Volrustomig (PD-1/CTLA-4 Bispecific)
1L Metastatic NSCLC
Sponsor AstraZeneca
1,100 Enrollment Target
220 Trial Sites
5 Countries
March 2028 Est. Completion
About This Trial
Novel bispecific antibody combining PD-1 and CTLA-4 blockade in single molecule.
Primary Endpoints
- Overall survival
- Progression-free survival
Latest Update
January 2026
Phase 2 showed 48% ORR in PD-L1 high patients. Pivotal Phase 3 enrollment progressing well.